SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or l5(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 1, 2019
UTAH MEDICAL PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
|
Utah
|
000-12575
|
87-0342734
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
7043 South 300 West
|
|
|
Midvale, Utah
|
84047
|
|
(Address of principal executive office)
|
|
|
Registrant's telephone number, including area code:
|
(801) 566-1200 |
n/a
(Former name or former address, if changed since last report)
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule l 4a- l 2 under the Exchange Act (17 CFR 240. l 4a- l 2) |
| [ ] | Pre-commencement communications pursuant to Rule l 4d-2(b) under the Exchange Act ( 17 CFR 240. l 4d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section l 3(a) of the Exchange Act. [ ]
ITEM 2.01-COMPLETION OF
ACQUISITION OR DISPOSITION OF ASSETS
UTMD made a cash payment of $21,000,000 to CSI on February l, 2019, and will purchase CSI's resaleable inventory for approximately $2,000,000.
ITEM 9.01-FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit Number* |
Title of Document
|
Location |
|
10.01 |
Agreement for the Purchase of Distribution Agreement, License Agreements, and Inventory between CooperSurgical, Inc., and Utah Medical Products, Inc., dated December 31, 2018 |
This Filing |
* All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
UTAH MEDICAL PRODUCTS, INC. |
|
|
Dated: February 12, 2019
|
By: /s/ Kevin L. Cornwell |
| Kevin L. Cornwell | |
|
|
Chairman & CEO |